Teva Pharmaceutical Industries Limited

NYSE:TEVA

Drug Manufacturers - Specialty & Generic

Healthcare
$42.23 -3.35%

-$1.09 today

Market cap
$49.28B
Beta
0.85
P/E (TTM)
23.1
EPS (TTM)
$1.36
52W Low $14.99High $37.35

Volume 8.86M

Average 6.22M

TEVA EBITDA Margin

EBITDA as a percentage of revenue.

Teva Pharmaceutical Industries LimitedNYSE: TEVA

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to -0.5%

EBITDA Margin was -0.5% in Q2 FY2026, down 16.2 pp from a year earlier. On a trailing-twelve-month basis it was 15.0%, down 2.9 pp year over year. Over 3 fiscal years it widened by 24.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 9 analysts of 27.9% for the fiscal year ending Dec 2026, up from 18.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-0.5%-22.5 pp QoQ
Last fiscal yearDec 2025
18.2%-8.6 pp YoY
LTMJun 2026
15.0%-2.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-16.2 pp+4.6 pp+20.8 pp
1 year-8.6 pp+9.7 pp+18.3 pp
3 years+24.4 pp+18.7 pp-5.7 pp
5 years+19.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
18.2%
Year-over-year change
-8.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TEVA compares with its peers on the latest reported figures

  • TEVA's LTM Jun 2026 EBITDA Margin of 15.0% is the 4th highest of the 5 companies compared; the peer median is 17.4%.
  • Its year-over-year change of -2.9 pp is the 3rd highest of 5, against a peer median of -6.0 pp.
  • Over three fiscal years its change of +24.4 pp compares with a peer median of -3.3 pp.
TEVA Competitors Peer median
EBITDA Margin for TEVA and competitors
Company Period LTM level YoY 3-year change
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202620.9% +0.5 pp+0.1 pp
VTRSViatris Inc.LTM Jun 202618.4% +21.9 pp-42.3 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202616.3% -12.5 pp-6.7 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202615.0% -2.9 pp+24.4 pp
ALVOAlvotechLTM Mar 20269.3% -14.4 pp+584.9 pp
Peer median (excluding TEVA) 17.4%-6.0 pp-3.3 pp

Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15.88B14.93B15.85B16.54B17.26B
Cost of Revenue8.28B7.95B8.2B8.48B8.32B
Gross Profit7.59B6.97B7.65B8.06B8.94B
Gross Margin47.8%46.7%48.2%48.7%51.8%
Research & Development1.09B838M953M1.06B1.01B
Selling, General & Admin3.53B3.45B3.5B3.7B3.97B
Operating Expenses5.88B9.17B7.21B8.37B6.78B
Depreciation & Amortization1.33B1.31B1.15B1.06B1B
EBITDA4.41B(925M)1.56B4.43B3.14B
EBITDA Margin27.8%-6.2%9.8%26.8%18.2%
Operating Income1.72B(2.2B)433M(303M)2.16B
Operating Margin10.8%-14.7%2.7%-1.8%12.5%
Interest Income0068M00
Interest Expense891M930M1.03B941M916M
Other Income / Expenses(1.05B)(945M)(1.06B)(980M)(919M)
Income Before Tax667M(3.14B)(622M)(1.28B)1.24B
Pre-Tax Margin4.2%-21.1%-3.9%-7.8%7.2%
Income Tax Expense211M(643M)(7M)676M(180M)
Net Income417M(2.45B)(559M)(1.64B)1.41B
Net Margin2.6%-16.4%-3.5%-9.9%8.2%
EPS (Basic)0.38(2.20)(0.50)(1.45)1.23
EPS (Diluted)0.38(2.20)(0.50)(1.45)1.20
Weighted Avg Shares1.1B1.11B1.12B1.13B1.15B
Weighted Avg Shares (Diluted)1.11B1.11B1.12B1.13B1.17B

Teva Pharmaceutical Industries Limited

NYSE:TEVA

Intrinsic Alpha fair value

Locked

Current Price

$42.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.